** Shares of drug developer Candel Therapeutics CADL.O more than double to $10.17 premarket
** Company says its cancer therapy CAN-2409 met the main goal of a late-stage trial in patients with a type of prostate cancer
** CAN-2409, along with radiation therapy, showed a statistically significant improvement in disease-free survival vs radiation therapy alone - CADL
** Disease-free survival is the length of time after treatment that a patient survives without any signs or symptoms of the disease
** Up to last close, stock up 213.6% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.